Similar articles for PMID: 10787361

Year	Number of Results
1970	1
1988	2
1991	1
1992	2
1995	1
1996	2
1997	5
1998	4
1999	9
2000	8
2001	17
2002	15
2003	12
2004	10
2005	9
2006	6
2007	5
2008	4
2009	7
2010	8
2011	4
2012	8
2013	4
2014	2
2015	7
2016	3
2017	4
2018	4
2019	2
2020	1
2021	1
2022	2
2023	1
2024	0

1

Postmenopausal hormone therapy increases risk for venous thromboembolic disease. The Heart and Estrogen/progestin Replacement Study.

Grady D, Wenger NK, Herrington D, Khan S, Furberg C, Hunninghake D, Vittinghoff E, Hulley S. Grady D, et al. Ann Intern Med. 2000 May 2;132(9):689-96. doi: 10.7326/0003-4819-132-9-200005020-00002. Ann Intern Med. 2000. PMID: 10787361 Clinical Trial.

2

Estrogen plus progestin and risk of venous thrombosis.

Cushman M, Kuller LH, Prentice R, Rodabough RJ, Psaty BM, Stafford RS, Sidney S, Rosendaal FR; Women's Health Initiative Investigators. Cushman M, et al. JAMA. 2004 Oct 6;292(13):1573-80. doi: 10.1001/jama.292.13.1573. JAMA. 2004. PMID: 15467059 Clinical Trial.

3

Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group.

Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vittinghoff E. Hulley S, et al. JAMA. 1998 Aug 19;280(7):605-13. doi: 10.1001/jama.280.7.605. JAMA. 1998. PMID: 9718051 Clinical Trial.

4

Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II).

Hulley S, Furberg C, Barrett-Connor E, Cauley J, Grady D, Haskell W, Knopp R, Lowery M, Satterfield S, Schrott H, Vittinghoff E, Hunninghake D; HERS Research Group. Hulley S, et al. JAMA. 2002 Jul 3;288(1):58-66. doi: 10.1001/jama.288.1.58. JAMA. 2002. PMID: 12090863 Clinical Trial.

5

Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial.

Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J; Writing Group for the Women's Health Initiative Investigators. Rossouw JE, et al. JAMA. 2002 Jul 17;288(3):321-33. doi: 10.1001/jama.288.3.321. JAMA. 2002. PMID: 12117397 Clinical Trial.

6

Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial.

Cauley JA, Robbins J, Chen Z, Cummings SR, Jackson RD, LaCroix AZ, LeBoff M, Lewis CE, McGowan J, Neuner J, Pettinger M, Stefanick ML, Wactawski-Wende J, Watts NB; Women's Health Initiative Investigators. Cauley JA, et al. JAMA. 2003 Oct 1;290(13):1729-38. doi: 10.1001/jama.290.13.1729. JAMA. 2003. PMID: 14519707 Clinical Trial.

7

Coronary heart disease in postmenopausal recipients of estrogen plus progestin therapy: does the increased risk ever disappear? A randomized trial.

Toh S, Hernández-Díaz S, Logan R, Rossouw JE, Hernán MA. Toh S, et al. Ann Intern Med. 2010 Feb 16;152(4):211-7. doi: 10.7326/0003-4819-152-4-201002160-00005. Ann Intern Med. 2010. PMID: 20157135 Free PMC article. Clinical Trial.

8

Effect of estrogen plus progestin on risk for biliary tract surgery in postmenopausal women with coronary artery disease. The Heart and Estrogen/progestin Replacement Study.

Simon JA, Hunninghake DB, Agarwal SK, Lin F, Cauley JA, Ireland CC, Pickar JH. Simon JA, et al. Ann Intern Med. 2001 Oct 2;135(7):493-501. doi: 10.7326/0003-4819-135-7-200110020-00008. Ann Intern Med. 2001. PMID: 11578152 Clinical Trial.

9

Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial.

Shumaker SA, Legault C, Rapp SR, Thal L, Wallace RB, Ockene JK, Hendrix SL, Jones BN 3rd, Assaf AR, Jackson RD, Kotchen JM, Wassertheil-Smoller S, Wactawski-Wende J; WHIMS Investigators. Shumaker SA, et al. JAMA. 2003 May 28;289(20):2651-62. doi: 10.1001/jama.289.20.2651. JAMA. 2003. PMID: 12771112 Clinical Trial.

10

Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study.

Shumaker SA, Legault C, Kuller L, Rapp SR, Thal L, Lane DS, Fillit H, Stefanick ML, Hendrix SL, Lewis CE, Masaki K, Coker LH; Women's Health Initiative Memory Study. Shumaker SA, et al. JAMA. 2004 Jun 23;291(24):2947-58. doi: 10.1001/jama.291.24.2947. JAMA. 2004. PMID: 15213206 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

165 results

Results by year